Vazalore, a liquid-filled aspirin capsule, has been made available by PLx Pharma.

Vazalore was approved by the Food and Drug Administration in March 2021. It is indicated for patients with vascular disease and those with rheumatologic diseases who are candidates for aspirin therapy. The product is designed to improve the absorption of aspirin by targeting the release of the active ingredient to various portions of the gastrointestinal (GI) tract.

In a randomized, active-controlled, single-blind, triple crossover pharmacokinetic and pharmacodynamic study, the time to complete antiplatelet effect (99% inhibition of thromboxane B2 generation) was observed to be significantly faster with Vazalore 325mg compared with enteric-coated aspirin 325mg (12.5 hours vs 48.2 hours, respectively) among obese patients with type 2 diabetes. Additionally, absorption was found to be 5 times as high as that of enteric-coated aspirin (P <.0001).

Continue Reading

Findings from a randomized, single-blind, active-controlled study evaluating upper GI damage following 7 days of aspirin therapy showed that Vazalore 325mg was associated with significantly fewer erosions and ulcers than immediate-release aspirin 325mg in healthy participants.

Vazalore is supplied as 81mg strength in 12-count blister packs and 30 count bottles and in 325mg strength in 30 count bottles.


PLx Pharma Inc.’s Vazalore Now on Shelves; National Media Campaign Launches Today. News release. Accessed August 26, 2021.

This article originally appeared on MPR